Late-onset thymidine kinase 2 deficiency: a review of 18 cases.
Adolescent
Adult
Child
DNA, Mitochondrial
/ genetics
Female
Humans
Late Onset Disorders
/ enzymology
Male
Middle Aged
Mitochondrial Myopathies
/ enzymology
Muscle, Skeletal
/ enzymology
Muscular Diseases
/ enzymology
Mutation
/ genetics
Retrospective Studies
Thymidine Kinase
/ deficiency
Young Adult
Mitochondrial myopathy
Multiple deletions
TK2 deficiency
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
06 05 2019
06 05 2019
Historique:
received:
05
02
2019
accepted:
17
04
2019
entrez:
8
5
2019
pubmed:
8
5
2019
medline:
26
11
2019
Statut:
epublish
Résumé
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity. We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12. The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients. The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.
Sections du résumé
BACKGROUND
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity.
METHODS
We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12.
RESULTS
The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients.
CONCLUSIONS
The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.
Identifiants
pubmed: 31060578
doi: 10.1186/s13023-019-1071-z
pii: 10.1186/s13023-019-1071-z
pmc: PMC6501326
doi:
Substances chimiques
DNA, Mitochondrial
0
thymidine kinase 2
EC 2.7.1.-
Thymidine Kinase
EC 2.7.1.21
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Subventions
Organisme : NINDS NIH HHS
ID : U54 NS078059
Pays : United States
Organisme : NICHD NIH HHS
ID : P01 HD080642
Pays : United States
Références
PLoS One. 2016 Feb 11;11(2):e0148709
pubmed: 26867126
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1539-1555
pubmed: 28215579
J Med Genet. 2018 Aug;55(8):515-521
pubmed: 29602790
Med Clin (Barc). 2000 Feb 5;114(4):121-7
pubmed: 10734620
Neuromuscul Disord. 2018 Oct;28(10):828-836
pubmed: 30166250
Neurology. 2008 Sep 2;71(10):758-65
pubmed: 18765652
J Int Med Res. 2018 Mar;46(3):1153-1161
pubmed: 29210305
Med Sci Sports Exerc. 2011 Aug;43(8):1465-73
pubmed: 21228724
Nat Genet. 2001 Nov;29(3):342-4
pubmed: 11687801
Essays Biochem. 2018 Jul 20;62(3):467-481
pubmed: 29980632
Mol Genet Metab. 2018 Jun;124(2):124-130
pubmed: 29735374
Pediatr Res. 2010 Aug;68(2):151-4
pubmed: 20421844
Brain. 2003 Feb;126(Pt 2):413-23
pubmed: 12538407
J Inherit Metab Dis. 2017 Jul;40(4):587-599
pubmed: 28324239
Neuromuscul Disord. 2018 May;28(5):408-413
pubmed: 29567350
Hum Mol Genet. 2012 Jan 1;21(1):66-75
pubmed: 21937588
Ann Neurol. 2017 May;81(5):641-652
pubmed: 28318037
Neurology. 2015 Jun 2;84(22):2286-8
pubmed: 25948719
Neuromuscul Disord. 2011 Aug;21(8):533-42
pubmed: 21676617
Med Sci Sports Exerc. 2018 Jun;50(6):1142-1151
pubmed: 29315169
Ann Neurol. 2015 Nov;78(5):814-23
pubmed: 26463265
Mitochondrion. 2009 Jul;9(4):242-6
pubmed: 19272467
J Neurol. 2015 Mar;262(3):701-10
pubmed: 25559684
BMC Genomics. 2014 Feb 01;15:91
pubmed: 24484525
Eur Radiol. 2018 Dec;28(12):5293-5303
pubmed: 29802573
Mol Genet Metab. 2013 Sep-Oct;110(1-2):35-41
pubmed: 23911206
Neurology. 2013 Dec 3;81(23):2051-3
pubmed: 24198295
Neurotherapeutics. 2013 Apr;10(2):186-98
pubmed: 23385875
Hum Mol Genet. 2014 May 1;23(9):2459-67
pubmed: 24362886